In a recent study published in Cancer Cell,Braun et al.introduced extracorporeal photopheresis(ECP)as a novel immunomodulatory approach to mitigate immune-related adverse events(irAEs)associated with immune checkpoint...In a recent study published in Cancer Cell,Braun et al.introduced extracorporeal photopheresis(ECP)as a novel immunomodulatory approach to mitigate immune-related adverse events(irAEs)associated with immune checkpoint inhibitors(ICIs)without compromising anti-tumor immunity.1 ECP suppressed Th1/Trm cell activation and neutrophil infiltration while enhancing an antiinflammatory macrophage phenotype through adiponectin,facilitating the resolution of steroid-refractory irAEs.展开更多
基金German Cancer Aid(Max-Eder Junior Research Group,ref.70115384)'funded by the Clinician Scientist Program of Heidelberg University,Faculty of Medicine and is part of the Cancer Core Europe(CCE)Training program of Young leaders in TRAnslational Cancer research(TRYTRAC).
文摘In a recent study published in Cancer Cell,Braun et al.introduced extracorporeal photopheresis(ECP)as a novel immunomodulatory approach to mitigate immune-related adverse events(irAEs)associated with immune checkpoint inhibitors(ICIs)without compromising anti-tumor immunity.1 ECP suppressed Th1/Trm cell activation and neutrophil infiltration while enhancing an antiinflammatory macrophage phenotype through adiponectin,facilitating the resolution of steroid-refractory irAEs.
